Signal Report · US
BMY HOLD
Composite decision report grounded in 1-XH strategy signals and multi-agent debate, generated by DeepSeek at 2026-07-02 08:50.
🎯 Final Decision
Action
HOLD
Weight
30%
Confidence
40%
Variant
xiaohan_gogo_v2
Reasons
- Bull case relies on same model for both technical and cross-sectional signals, not independent confirmation.
- Bear case's backward-looking momentum drags are valid but expected at a potential reversal point.
- No fundamental catalyst and weak composite z-score (+0.59) reduce conviction in either direction.
- Regime tilt is bullish but not strong enough to override mixed signals; prefer to wait for clearer evidence.
Bull Case (Analyst)
- The technical signal is strongly bullish: the 1-XH family issues a buy with a score of 0.80, and the gogo_detail shows bottoms on 1h through 4h timeframes plus a daily bottom, suggesting a multi-timeframe reversal setup. - The cross-sectional factor view is supportive: BMY ranks 5th out of 251 stocks (top 2.0%) with a composite z-score of +0.59 in a BULL catalog, indicating strong relative strength in the current regime. - The top lifter is xh_gogo_score at +2.81 z, directly corroborating the technical buy signal — the same factor driving the rank is the one flashing a buy, creating a powerful alignment between cross-section and time-series. - Downside_vol_60d (+0.67) and drawdown_3m (+0.44) are positive contributors, suggesting the stock has already experienced significant volatility and drawdown, potentially setting up for mean reversion higher from current levels.
Bear Case (Analyst)
- The cross-sectional factor view explicitly notes BMY is NOT in the production basket — despite a high composite z, the model did not select it for the top decile, implying the signal may be less actionable than the rank suggests. - Top draggers are fundamental quality and momentum metrics: sharpe_60d (-0.74) and close_to_high_60d (-0.49) indicate poor risk-adjusted returns and price weakness relative to recent highs over the past 60 days. - Beta_60d (-0.35) is a drag, suggesting the stock has been moving against the broader market, which could mean the technical bottom signals are catching a falling knife rather than a genuine reversal. - The only news item is about AbbVie acquiring Apogee — a competitor in immunology — with no direct relevance to BMY, providing no fundamental catalyst to support the technical buy signal.
Devil's Advocate
COUNTER TO BULL: - The 1-XH family buy score of 0.80 is not a 1.0 — it's still a probabilistic signal, and multi-timeframe bottoms can form repeatedly in a downtrend before a real reversal (or no reversal at all). - BMY's top 2% rank is in a BULL catalog, but the composite z-score is only +0.59 — that's weak sauce for a top decile stock, suggesting the factor environment is not strongly bullish overall. - The alignment between xh_gogo_score and the technical buy is circular: the same model that generated the signal also drives the rank. This is not independent confirmation; it's the same flawed coin flipped twice. - Downside_vol_60d and drawdown_3m being positive contributors is a hidden assumption that mean reversion is guaranteed. High vol and deep drawdowns can just as easily precede further downside, especially in a stock with no catalyst. COUNTER TO BEAR: - "Not in production basket" is a model-specific filter, not a fundamental rejection. The rank still says top 2% — the basket exclusion could be due to liquidity, sector constraints, or stale rules, not signal weakness. - Sharpe_60d and close_to_high_60d are backward-looking. A multi-timeframe bottom signal is explicitly trying to catch the turn *after* poor momentum — these draggers are the reason the technical setup exists, not a contradiction. - Beta_60d being negative means BMY has been a defensive stock in a risk-on market. That could reverse if the market rotates into defensives — the bear case assumes the current regime persists indefinitely. - The AbbVie/Apogee news is irrelevant to BMY, but the bull case doesn't need a catalyst if the technical and cross-sectional signals are genuine. Absence of news is not evidence against a reversal — it just means the move is purely technical.
Technical Signal (1-XH)
action
buy
score
0.80
variant
xiaohan_gogo_v2
timestamp
2026-07-01 15:30:00
close
56.46
ema_low_fast
56.8
ema_high_slow
56.69
gogo_score
0.8
gogo_detail
1h_bottom,2h_bottom,3h_bottom,4h_bottom,1h_blue_upper_above_yellow_upper,daily_bottom
📈 Backtest Track Record xiaohan_gogo_v2 · signals simulated over available history (~3-month 30-min window, accumulating daily)
Trades
1
Win rate
100%
Avg / trade
+1.7%
Total (compounded)
+2%
best / worst
+1.7% / +1.7%
avg holding
8.2 days
open position
yes — marked-to-market +1.7%
| Entry | Exit | Entry | Exit | Return | Exit reason |
|---|---|---|---|---|---|
| 2026-06-23 | open | 55.52 | 56.46 | +1.7% | open_position_mark_to_market |
News & social (1 items)
-
wsj.comAbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion - WSJThis copy is for your personal, non-commercial use only. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/business/deals/abbvie-to-buy-apo…